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Summary 
We conducted an observational study of 30 heart transplant recipients with serum low-density lipoprotein cholesterol 
(LDL-c) >100 mg/dl despite previous statin therapy, who were treated with rosuvastatin 10 mg daily (5 mg in case of 
renal dysfunction). Serum lipids, creatine phosphokinase (CPK), bilirubin, and hepatic enzymes were prospectively 
measured 2, 4, and 12 weeks after the initiation of the drug. Clinical outcomes of patients who continued on long-
term rosuvastatin therapy beyond this 12-week period were reviewed in February 2015. Over the 12-week period 
following rosuvastatin initiation, serum levels of total cholesterol (TC) and LDL-c and the ratio TC/high-density 
lipoprotein cholesterol (HDL-c) decreased steadily (P < 0.001). Average absolute reductions of these three 
parameters were –48.7 mg/dl, –46.6 mg/dl, and –0.9, respectively. Seventeen (57%) achieved a serum LDL-
c < 100 mg/dl. No significant changes from baseline were observed in serum levels of triglycerides, HDL-c, hepatic 
enzymes, bilirubin, or CPK. Twenty-seven (90%) patients continued on long-term therapy with rosuvastatin over a 
median period of 3.6 years, with no further significant variation in lipid profile. The drug was suspended due to liver 
toxicity in 1 (3.3%) patient and due to muscle toxicity in 2 (6.7%) patients. All adverse reactions resolved rapidly 
after rosuvastatin withdrawal. Our study supports rosuvastatin as a reasonable alternative for heart transplant 
recipients with hypercholesterolemia and therapeutic failure of other statin regimens. 
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Introduction 
Statins are cholesterol-lowering agents that inhibit the endogenous synthesis of cholesterol by 
blocking the hydroxymethylglutaryl-CoA reductase. In patients with previous history of coronary artery 
disease and in those with high cardiovascular risk, chronic treatment with statins has shown a significant 
reduction in serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c), as 
well as a decreased incidence of cardiovascular events [1, 2]. 
 
Hypercholesterolemia is a common comorbidity in patients with heart transplantation (HT), with a 
prevalence reaching 60–80% [3, 4]. Hypercholesterolemia may occur as a pre-existing condition, but also 
as a side effect of immunosuppressive therapy [5], leading to an increased risk of cardiovascular disease 
and mortality, as well as to the development of coronary allograft vasculopathy [6]. In HT patients, statin 
therapy has shown a significant reduction in the incidence of acute rejection and CAV and increased 
long-term survival [7, 8]. However, the use of statins in this population is conditioned by its potential 
interactions with immunosuppressive therapy and an increased risk of adverse events [9, 10]. 
 
Rosuvastatin is a synthetic statin [11] with high lipid-lowering power and a suitable safety profile 
derived from its hydrophilic nature. So far, only a small observational study has evaluated its clinical 
usefulness in patients with HT. In this previous report [12], rosuvastatin showed good efficacy and a low 
rate of serious adverse events over limited follow-up of 6 weeks. To the best of our knowledge, however, 
no long-term clinical data about the clinical usefulness of this drug in the HT population have been 
reported until now. 
 
The aim of our study was to assess the efficacy and safety of rosuvastatin therapy in HT patients with 
uncontrolled hypercholesterolemia despite previous treatment with other statin regimens, both in the short 
term and also in the long term. 
Methods 
Study protocol 
We conducted a prospective observational study between September 2009 and March 2010. A total of 
30 patients with HT who had a serum LDL-c > 100 mg/dl despite statin therapy at the highest tolerated 
dose or in which statins had been discontinued indefinitely due to adverse reactions were included. 
Concomitant treatment with other lipid-lowering agents, such as ezetimibe, was considered an exclusion 
criterion for the study. 
 
After discontinuing previous treatment, patients initiated rosuvastatin 10 mg/day in a single oral 
nightly dose. Starting dose was reduced to 5 mg in patients who showed a serum creatinine >1.5 mg/dl at 
baseline, allowing dose escalation to 10 mg/day after four weeks, only if they showed good tolerance, no 
adverse effects and serum LDL-c remained above 100 mg/dl. 
 
All patients received immunosuppressive treatment with varying doses of oral prednisone depending 
on the time passed after HT and the number of previous episodes of graft rejection. Patients also received 
a combination of at least two of the following three drug groups: (i) calcineurin inhibitors (cyclosporine 
or tacrolimus), (ii) mTOR inhibitors (everolimus or sirolimus), and (iii) mycophenolate mofetil or sodium 
mycophenolate. 
 
According to a predefined protocol, scheduled clinical visits were conducted at 2, 4, and 12 weeks 
after initiation of treatment. At every visit, analytical tests were performed, including the determination of 
plasma levels of TC, triglycerides, LDL-c, HDL-c, bilirubin, creatinine phosphokinase (CPK), glutamate 
oxaloacetate transaminase (GOT), and glutamate pyruvate transaminase (GPT). Patients were enquired 
about tolerability and potential side effects of the study drug. Patients who showed an LDL-c < 100 mg/dl 
at the end of this 12-week follow-up period were considered as “responders” to rosuvastatin therapy. 
Secondary therapeutic goals were a serum TC <200 mg/dl, serum triglyceride <150 mg/dl, and a 
TC/HDL-c ratio <4. 
  
In February 2015, we conducted a retrospective review of long-term clinical outcomes of patients who 
continued on rosuvastatin therapy beyond the predefined 12-week follow-up period on the basis of the 
clinical criterion of their attending cardiologist. The occurrence of drug-related adverse reactions and 
cardiovascular events (coronary and cerebrovascular) over long-term follow-up was recorded. Laboratory 
data at the time of the last clinical visit were also collected. 
Definitions 
Liver toxicity was defined as the elevation of serum GPT and/or GOT >3 times the upper limit of 
standard reference values [12]. Episodes of muscle toxicity were classified according to the Canadian 
Working Group [13] definitions: 
 
1. Myalgia: muscle symptoms with normal or mildly elevated serum CPK levels. 
2. Mild CPK elevation: asymptomatic elevation of serum CPK levels up to 10 times the upper limit of 
normality. 
3. Rhabdomyolysis: muscle symptoms and serum CPK levels >10 times the upper limit of normality (or 
>10 000 IU/l), myoglobinuria, renal failure, or need for hydration. 
 
The comparison of the daily doses of statins that patients were receiving before entering the study was 
conducted through the conversion to pravastatin equivalents, by applying the following conversion ratio: 
40 mg pravastatin = 10 mg atorvastatin = 80 mg fluvastatin. 
Statistical analysis 
In this study, categorical variables are presented as proportions and continuous variables are presented 
as median (interquartile range, IQR), due to a small sample size and asymmetrical distributions. 
 
The trend of the serum levels of TC, LDL-c, HDL-c, triglycerides, TC/HDL-c ratio, GOT, GPT, and 
CPK over the predefined 12-week follow-up period is depicted using box-plot graphs, and statistical 
comparison was conducted using the nonparametric Friedman test for multiple repeated measures. To 
estimate the absolute and relative mean reductions in serum total cholesterol, LDL-c, triglycerides, and 
TC/HDL-c ratio after 12 weeks of treatment as compared to baseline, we first computed these differences 
for each of the patients and then we subsequently calculated the mean and standard deviation (SD) of 
these distributions. Statistical analysis was performed by means of IBM SPSS Statistics for Macintosh, 
Version 20.0 (IBM Corp, Armonk, NY, USA) and epidat 4.1 (Consellería de Sanidade, Xunta de Galicia, 
Spain). Statistical significance was set as a P value <0.05. 
Results 
Baseline clinical characteristics 
Of the 30 patients studied, 4 (13%) were women. The median age of the sample was 60.2 years (IQR: 
53.3–67.4) and the median time elapsed since HT was 4.2 years (IQR: 1.3–9.4). 
 
At baseline, median TC was 236 mg/dl (IQR: 214–264), median triglycerides were 159 mg/dl (IQR: 
118–249), median LDL-c was 142 mg/dl (IQR: 125–162), median HDL-c was 56 mg/dl (IQR: 43–69), 
and median TC/HDL-c ratio was 4.5 (IQR: 3.7–5.3). According to inclusion criteria, all patients presented 
LDL-c > 100 mg/dl. In addition, 27 patients (90%) presented TC> 200 mg/dl, 17 (57%) had triglycerides 
> 150 mg/dl, and 11 (63%) had a TC/HDL-c ratio > 4. 
 
Just before entering the study, 26 (87%) patients were being treated with statins at maximum tolerated 
doses (14 pravastatin, 11 atorvastatin, and 1 fluvastatin). The mean equivalent daily dose of pravastatin 
was 36 mg (IQR: 20–40 mg). Four patients (13%) had received statins in the past, but they had been 
suspended indefinitely due to adverse reactions (3 cases of liver toxicity and 1 case of muscular toxicity). 
Table 1 shows the baseline characteristics of the study population. 
  
Table 1. Clinical characteristics of study participants 
  
Age (years), median (IQR) 60.2 (53.3–67.4) 
Female (n, %) 4 (15%) 
Diabetes mellitus 6 (20%) 
Hypertension 20 (67%) 
Immunosuppressive therapy 
Cyclosporine 9 (30%) 
Tacrolimus 15 (50%) 
Sirolimus or everolimus 13 (43%) 
Mycophenolate mofetil 21 (70%) 
Prednisone 30 (100%) 
Current treatment with statins 26 (87%) 
Pravastatin 11 (37%) 
Atorvastatin 9 (33%) 
Fluvastatin 1 (3%) 
Pravastatin equivalent daily dose (mg), median (IQR) 36 (20–40) 
Prior statin toxicity 
Hepatotoxicity 3 (10%) 
Muscle toxicity 1 (3%) 
Body mass index (kg/m2), median (IQR) 27.4 (25.4–30.6) 
Time since HT (years), median (IQR) 4.2 (1.3–9.4) 
Baseline laboratory parameters, median (IQR) 
Total cholesterol (mg/dl) 236 (214–264) 
LDL cholesterol (mg/dl) 142 (125–162) 
HDL cholesterol (mg/dl) 56 (43–69) 
Triglycerides (mg/dl) 159 (118–249) 
Creatinine (mg/dl) 1.35 (1.15–1.65) 
Total bilirubin (mg/dl) 0.6 (0.3–0.8) 
GOT (IU/l) 21 (18–33) 
GPT (IU/l) 25 (17–33) 
CPK (IU/l) 92 (51–155) 
  
 
CPK, creatine phosphokinase; GOT, glutamate oxaloacetate transaminase; GPT, 
glutamate pyruvate transaminase, IQR, interquartile range; HT, heart 
transplantation. 
 
Rosuvastatin was initiated at the standard dose of 10 mg/day in 20 (67%) patients, while the reduced 
dose of 5 mg/day was initiated in 10 (33%) patients who had baseline serum creatinine >1.5 mg/dl. In the 
latter group, the dose of rosuvastatin was increased in 6 patients to 10 mg/day after 4 weeks of treatment 
with the initial dose, due to the persistence of serum LDL-c > 100 mg/dl. 
Changes in lipid profile 
Over the predefined 12-week follow-up period, statistically significant decreasing trends in TC 
(P < 0.001), LDL-c (P < 0.001), and TC/HDL-c ratio (P < 0.001) were observed (Fig. 1). As compared to 
baseline, rosuvastatin therapy resulted in an average absolute reduction of –48.7 mg/dl (confidence 
interval (CI) 95%: –34.2 to –63.1) in TC and –46.6 mg/dl (CI 95% –33.5 to –59.7) in LDL-c, which 
represented an average relative reduction in these parameters of –20.1% (CI 95% –14.7% to –25.5%) and 
–19.2% (CI 95% –14.6% to –23.8%), respectively. The TC/HDL-c ratio experienced an average absolute 
reduction of –0.9 (CI 95% –0.5 to –1.3), although no significant variation in HDL-c (P = 0.99) was 
detected. An average absolute reduction of –16.1 mg/dl (CI 95% –40.3 to +8.3) in triglycerides was also 
observed, but the decreasing trend of this parameter over time did not reach statistical significance 
(P = 0.16). At the end of this period, 18 patients (60%) showed serum TC < 200 mg/dl, 17 patients (57%) 
showed serum LDL-c < 100 mg/dl, and 21 (70%) patients showed a TC/HDL-c ratio <4. Only 14 patients 
(47%) presented serum triglycerides <150 mg/dl. 
 
 
 
Figure 1. Evolution of serum total cholesterol (mg/dl, panel a), LDL cholesterol (mg/dl, panel b), total cholesterol total/HDL ratio 
(panel c), HDL cholesterol (mg/dl, panel d) and triglyceride levels (mg/dl, panel e) over a 12-week follow-up period after the 
initiation of rosuvastatin. Numeric values refer to medians. 
Clinical profile of responders 
The Table 2 shows the baseline clinical characteristics of “responders”—that is, patients who reached 
a serum LDL-c< 100 mg/dl—and “nonresponders”—that is, patients who did not. Statistically significant 
differences were found with regard to the time elapsed since HT, which was shorter in the former group 
(median 2.6 versus 8.5 years, P = 0.035), and baseline serum levels of TC (median 222 versus 259 mg/dl, 
P = 0.01) and LDL-c (median 155 versus 130 mg/dl, P = 0.01), which were higher in the latter. Before 
the start of rosuvastatin therapy, most of “nonresponders” were being treated with atorvastatin (62%), 
while most of “responders” were being treated with pravastatin (71%). Equivalent daily doses of previous 
statin therapy were significantly higher among “nonresponders” than among “responders” (median 40 
versus 20 mg, P = 0.043). 
 
  
Table 2. Baseline clinical characteristics of patients who had an LDL-c < 100 mg/dl at the end of the 12-week follow-up period 
(“responders”) in comparison with those who had not (“nonresponders”) 
  Responders Nonresponders P 
Age (years), median (IQR) 59.7 60.1 () 0.263 
Female (n, %) 2 (12%) 2 (15%) 0.773 
Diabetes mellitus 4 (23%) 2 (15%) 0.672 
Hypertension 11 (65%) 9 (69%) 0.794 
Immunosuppressive therapy 
Cyclosporine 3 (18%) 6 (46%) 0.091 
Tacrolimus 11 (65%) 4 (31%) 0.065 
Sirolimus or Everolimus 6 (35%) 7 (54%) 0.31 
Mycophenolate mofetil 14 (82%) 7 (58%) 0.091 
Prednisone 17 (100%) 13 (100%) 1 
Current treatment with statins 
Pravastatin 12 (71%) 2 (15%) 
0.018 
Atorvastatin 3 (18%) 8 (62%) 
Fluvastatin 0 1 (3%) 
None 2 (12%) 2 (2%) 
Pravastatin equivalent daily dose (mg), median (IQR) 20 (20–20) 40 (10–70) 0.043 
Prior statin toxicity 2 (12%) 2 (15%) 0.773 
Hepatotoxicity 2 (12%) 1 (8%) 0.713 
Muscle toxicity 0 1 (8%) 0.433 
Body mass index (kg/m2), median (IQR) 27.8 (24.3–33.3) 27.1 (26.4–29.4) 1 
Time since HT (years), median (IQR) 2.6 (0.9–5.6) 8.5 (2–12.5) 0.035 
Baseline laboratory parameters, median (IQR) 
Total cholesterol (mg/dl) 222 (203–244) 259 (239–305) <0.001 
LDL cholesterol (mg/dl) 130 (115–143) 155 (142–207) <0.001 
HDL cholesterol (mg/dl) 57 (42–70) 55 (44–69) 0.65 
Triglycerides (mg/dl) 156 (108–239) 167 (124–255) 0.837 
Creatinine (mg/dl) 1.4 (1.2–1.8) 1.2 (1.1–1.4) 0.186 
Total bilirubin (mg/dl) 0.6 (0.4–0.9) 0.6 (0.5–0.9) 0.805 
GOT (IU/l) 20 (19–26) 33 (19–43) 0.123 
GPT (IU/l) 24 (18–29) 29 (17–45) 0.245 
CPK (IU/l) 82 (50–123) 143 (57–278) 0.079 
    
 
CPK, creatine phosphokinase; GOT, glutamate oxaloacetate oxalate transaminase; GPT, glutamate pyruvate transaminase, IQR, 
interquartile range; HT, heart transplantation. 
 
There was a trend to a higher use of tacrolimus and a lower use of cyclosporine A among 
“responders,” but this difference did not reach statistical significance. No significant differences between 
both groups were observed with regard to the use of mycophenolate mophetil or mTOR inhibitors. 
Long-term follow-up 
Beyond the end of the predefined 12-week follow-up period, 27 (90%) patients continued on 
rosuvastatin therapy by clinical decision. At this moment, drug discontinuation was due to side effects in 
two cases, as detailed in the specific chapter of Adverse Reactions (page 10). 
 
Treatment was maintained for a median time of 1772 days (IQR 1107–1877). Twenty-three patients 
were treated exclusively with rosuvastatin, and 4 patients also received ezetimibe in combination. At the 
last clinical visit, median serum levels of TC, LDL-c, HDL-c, and triglycerides were, respectively, 
179 mg/dl (IQR: 142–215), 97 mg/dl (IQR: 72–114), 49 mg/dl (IQR: 41–65), and 154 mg/dl (IQR: 87–
215), and median TC/HDL-c ratio was 3.3 (IQR: 2.9–4). No variation of serum lipid levels from the end 
of the predefined 12-week follow-up period to the end of long-term follow-up was statistically significant 
(P > 0.05 for all comparisons). The proportion of patients who reached the secondary therapeutic goals 
for TC (<200 mg/dl), LDL-c (<100 mg/dl), triglycerides (<150 mg/dl), and TC/HDL-c ratio (<4) at the 
end of long-term follow-up were 67%, 63%, 48%, and 73%, respectively. No coronary or cerebrovascular 
event occurred over long-term follow-up in studied patients. 
Adverse reactions 
No significant changes in the distribution of serum levels of GOT, GPT, bilirubin, or CPK in the study 
population were observed during the predefined 12-week follow-up period after the initiation of 
rosuvastatin (Fig. 2). 
 
 
 
Figure 2. Evolution of serum levels of CPK (IU/liter, panel a), total bilirubin (mg/dl, panel b), 
GOT (UI/liter, panel c) and GPT (IU/l, panel d) during a 12-week follow-up period after the 
initiation of rosuvastatin. Numeric values refer to medians. °,outliers, *,extreme values. 
Over the whole follow-up of the study, rosuvastatin was suspended in 2 (6.7%) patients due to muscle 
toxicity—1 case of rhabdomyolysis and 1 case of myalgia without CPK elevation—and in 1 (3.3%) 
patient due to liver toxicity—asymptomatic elevation of transaminases, so as resulting in an incidence 
rate of adverse reactions leading to drug suspension of 2.78 episodes per 100 patient-years—1.85 
episodes of muscle toxicity per 100 patient-years and 0.93 episodes of liver toxicity per 100 patient-years. 
The onset of these three cases of toxicity was 21, 25, and 318 days after the initiation of rosuvastatin 
therapy, respectively. 
 
Both patients with muscular toxicity received concomitant therapy with cyclosporine and everolimus 
when rosuvastatin was initiated. At the time of the side effect, serum levels of cyclosporine were within 
the normal range (79.9 and 60.1 ng/ml), but one patient presented slight everolimus overdose (8.5 ng/ml). 
The patient with liver toxicity was being treated with mycophenolate and tacrolimus. Both this patient 
and the patient with myalgia had already presented similar adverse reactions to other statins previously. 
All adverse events resolved within a few days after drug withdrawal without requiring any other specific 
therapeutic intervention and without permanent sequelae. 
  
Discussion 
The results of our study suggest that rosuvastatin therapy is effective in reducing TC and LDL-c in 
patients with HT in which other statin regimens have failed to achieve the recommended therapeutic 
goals. Moreover, this benefit is not accompanied by an undesirable incidence of adverse effects. 
 
Practice guidelines recommend chronic statin therapy in all patients with HT [3]. In this population, 
the rationale for statin therapy goes beyond their lipid-lowering action or cardiovascular risk reduction, as 
they are also thought to act as immune modulators [14]. Two randomized clinical trials have studied the 
potential clinical benefit of pravastatin [7] and simvastatin in patients with HT [8], showing a significant 
reduction in the incidence of acute rejection and coronary allograft vasculopathy and an improvement in 
long-term survival compared to the placebo group. This occurs in addition to the expected reduction in 
total serum cholesterol and LDL cholesterol. 
 
In the general population with hypercholesterolemia, treatment with 10 mg/day of rosuvastatin leads 
to an average relative reduction in serum LDL-c levels of 46% [10], which is comparable to that obtained 
with high doses of atorvastatin (40 mg/day) or simvastatin (80 mg/day). In our study, the mean relative 
reduction in LDL-c was significantly lower (19%), similar to what was observed in a previous study in 
patients with HT [12]. Although we cannot rule out the hypothesis of a poor response to the drug in 
patients with HT compared to the general population, our view is that this discrepancy may be explained 
by a selection bias resulting from the inclusion criteria of the study, as all patients included had a plasma 
LDL-c level >100 mg/dl despite previous statin treatment, with a median daily dose equivalent to 36 mg 
of pravastatin. The frequent use of proliferation signal inhibitors is another important factor to take into 
account, given that these drugs may induce dyslipidemia difficult to control despite treatment with lipid-
lowering agents [15]. In our series, as it has been shown in other studies [12, 16], we observed no 
significant effect of rosuvastatin on serum HDL cholesterol levels. The slight reduction in plasma 
triglyceride levels observed in our study showed no statistical significance, contrarily to what was 
reported by other authors [12, 16]. 
 
In our study, 57% patients treated with rosuvastatin achieved a LDL-c level <100 mg/dl. This 
proportion is slightly lower than that observed by Samman et al. [12]. Nonetheless, we feel that it is a 
relevant reduction, taking into account that all patients presented with levels above this threshold before 
the start of the study, due to insufficient response or intolerance to other statins. By analogy to the 
recommendations of lipid control in patients with high cardiovascular risk [17], some authors argue that 
an LDL-c level <100 mg/dl might be a reasonable target to pursue in most patients with HT [18], given 
the high prevalence of risk factors in this population. However, the risk–benefit ratio of this strategy must 
be individualized, given the known increased susceptibility to drug toxicity of HT recipients [9, 10]. 
 
A major strength of our investigation in comparison with the previous study [12] of rosuvastatin in 
HT recipients is the availability of long-term results. Because of clinical decision, 90% of patients 
continued on rosuvastatin therapy after the pre-defined 12-week follow-up period of the study, with a 
median period of time on treatment of ~3.5 years. Serum levels of LDL-c and TC at the last clinical visit 
remained unchanged in comparison with the end of the predefined 12-week follow-up period, so as 
supporting the sustained efficacy of rosuvastatin therapy in the HT population in the long term. The 
proportion of patients matching the therapeutic goal of a serum LDL-c < 100 mg/dl in the long term was 
63%, and this proportion was even slightly higher for other secondary therapeutic goals of lipid profile as 
a TC <200 mg/dl (67%) or a TC/HDL-c ratio <4 (73%). Interestingly, no cerebrovascular or coronary 
event occurred among studied subjects over long-term follow-up. Despite it is a good result, the study 
was not designed, nor powered, to detect clinical events, so no conclusion may be extracted about the 
efficacy of the drug to prevent cardiovascular complications in the HT population. 
 
Trying to identify baseline clinical characteristics that might be associated with a higher probability of 
experiencing a significant therapeutic response to rosuvastatin therapy, we conducted an exploratory, 
descriptive analysis comparing the clinical profile of patients who reached a LDL-c < 100 mg/dl after 
treatment onset (“responders”) and patients who did not (“nonresponders”). A shorter time since HT to 
treatment onset, a lower baseline LDL-c and a lower intensity of previously failed statin therapy seemed 
to be the unique clinical characteristics that precluded a higher probability for a patient to become a 
“responder.” This conclusion, however, must be taken with caution, as the limited size of the study 
sample prevented us to conduct the required multivariable adjustment. 
  
In the general population, adverse reactions to statins are infrequent and dose-related and usually 
disappear after drug withdrawal [19]. The most common adverse event following statin therapy is muscle 
pain, which can occur in up to 5% of patients, although the incidence of severe myopathy is lower than 
0.2% [20, 21]. Liver toxicity is also infrequent, as it occurs in less than 2% of patients treated with statins, 
usually in an asymptomatic manner, and disappears after discontinuation of treatment [22]. In an 
exhaustive review [23] of more than 16 000 patients enrolled in clinical trials comparing rosuvastatin vs. 
other statins, the reported cumulative incidence of liver toxicity and muscle toxicity was, respectively, 
0.2% and 0.3%. The hydrophilic nature of rosuvastatin and its low affinity for the hepatic cytochrome 
P450 are the proposed reasons for the apparently good safety profile of this drug [24]. 
 
In patients with HT, there is an increased risk of statin-related muscle and liver toxicity [9, 10], which 
is attributed to drug–drug interactions with immunosuppressive agents [25]. In the case of rosuvastatin, 
the risk of interaction is especially high with cyclosporine, which induces a competitive inhibition of the 
liver transporter organic anion transporting polypeptide C [26]. This protein is essential for the 
degradation of drug; because of this, concomitant treatment with rosuvastatin and cyclosporine usually 
results in an increased plasmatic concentration of the lipid-lowering agent. 
 
Over a ~3.5-year follow-up, we detected two cases (6.7%) of muscle toxicity and one case (3.3%) of 
liver toxicity associated with rosuvastatin, which were not life-threatening and reversed without sequelae 
after drug withdrawal. Both cases of muscular toxicity appeared early (<30 days) after the initiation of the 
drug, and the other was detected after ~10 months on treatment. With variable lengths of treatment 
duration among studies, the reported cumulative incidence of statin-related toxicity in the HT population 
was around 8% with atorvastatin [27], 13% with fluvastatin [28] and simvastatin [29], and significantly 
lower with pravastatin [29]. In a previous study by our own group, we observed an overall cumulative 
incidence of statin toxicity of 12% [9] in HT patients, being obesity the only risk factor independently 
associated with this complication. Samman et al. [12] detected 1 case of myalgia and two cases of 
asymptomatic mild CPK elevation in their cohort of 20 HT patients treated with rosuvastatin for a 6-week 
period. 
 
Given that the cumulative incidence of adverse reactions to rosuvastatin in our study was at least not 
higher than reported in studies with other statins in the HT population, that our series included a 
significant proportion (13%) of patients with previous adverse reactions to other statins—indeed, two of 
the three cases of toxicity occurred in patients with this antecedent—and that all adverse effects were 
reversible after drug withdrawal, we conclude that rosuvastatin is a reasonably safe therapeutic alternative 
in HT patients. Notwithstanding this, careful monitoring and a high level of clinical suspicion about 
potential adverse effects should be maintained when prescribing rosuvastatin—or other statins—to a HT 
recipient. 
 
In conclusion, our study supports rosuvastatin as a good alternative for the treatment of uncontrolled 
hypercholesterolemia in HT recipients with a poor previous response to other statins. Rosuvastatin 
showed to be effective to reduce serum levels of TC and LDL-c, allowing that more than a half of such 
patients reach the recommended therapeutic goals for lipid profile. This result was achieved at the 
expense of rate of adverse reactions clearly higher than that observed in patients from the general 
population, but similar to observed with other statins in the HT population. Larger studies are warranted 
to elucidate the potential benefit of rosuvastatin in terms of cardiovascular mortality and survival in HT 
patients. 
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